Human Paratuberculosis Foundation is dedicated to providing the most up-to-date information in our field to assist patients around the world in making informed decisions about their treatment. We are grateful for the support of this community and look forward to taking this journey together.
Read all the latest news and research about Mycobacterium avium subsp. paratuberculosis (MAP) and the treatment of Crohn’s and other diseases using AMAT therapy. Enjoy!
On my way home from the 2017 MAP Conference in Philadelphia, I had to drive through a tunnel which ran underneath a mountain. Tunnels have always made me a little nervous due the confinement, but I relaxed as I saw daylight coming from a small hole on the other side. As I focused on getting to the light, it occurred to me that this tunnel was a great representation of my journey with Crohn’s disease. For so many years I moved forward through life in the confinement of disease. Darkness was my companion, and I felt alone and different from those around me. But as my body healed on antibiotic therapy, I came back into the light of living a full and joyful life free of chronic disease.
The following article was provided to Human Paratuberculosis Foundation by Dr. Judith Lipton. It was written in May 2015, but still remains relevant today. It is an excellent overview of MAP, and provides practical advice for patients who want to convince their doctor to treat their MAP infection. HPF is grateful to Dr. Lipton for her contributions to the field and for providing this helpful article.
UPDATE: On March 24-25, 2017, MAP researchers and doctors from around the world will gather in Philadelphia, PA to share presentations and discuss how best to advance MAP science. Read the latest update about the Goals of the meeting, Discussion Topics, and Presenters list. Additionally, the latest sponsorship details are announced.
There are at least two ways that bacteria may play a role in inflammatory bowel disease. The top of the Hit Parade at present is the gut microbiome. Researchers, by using complex new technologies, can take a virtual snapshot of the bacterial DNA in the gut of the IBD patient (and in the normal patient, of course). Successful snapshots end up as publications if they demonstrate a difference in the gut microbiome between these two groups. If the IBD patient shows an abundance of a particular organism when it is not apparent in the control group, then this may indicate the presence of an organism capable of triggering an inflammatory reaction in the gut of the patient.